

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Sacubitril/Valsartan (Entresol®) for treating symptomatic chronic heart failure with reduced ejection fraction
Policy No:	PCN 206-2016
Date of Issue	June 2016
Review Date:	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p>Recommendations: The PCN recommends Sacubitril/Valsartan (Entresol®) for treating symptomatic chronic heart failure with reduced ejection fraction in line with NICE guidance (TA388 – April 2016) and will be considered as AMBER on the traffic light system.</p> <p>CCGs in conjunction with local Acute Trusts will make local implementation plans as required</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA388 (April 2016) Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. https://www.nice.org.uk/guidance/ta388/resources/sacubitril-valsartan-for-treating-symptomatic-chronic-heart-failure-with-reduced-ejection-fraction82602856425157 	
Date taken to Area Prescribing Committee	June 2016
Agreed by APC members	21st June 2016